Xenon Pharmaceuticals Inc. (XENE) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
XENE EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
XENE Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 66.1% | -4974.3% | -4612.1% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | 100.0% | -1368.9% | -1328.9% |
| 2021 | 100.0% | -428.4% | -427.8% |
Download Data
Export XENE earnings history in CSV or JSON format
Free sign-in required to download data
Xenon Pharmaceuticals Inc. (XENE) Earnings Overview
As of May 8, 2026, Xenon Pharmaceuticals Inc. (XENE) reported trailing twelve-month net income of -$383M, reflecting -44.9% year-over-year growth. The company earned $-4.39 per diluted share over the past four quarters, with a net profit margin of -4612.1%.
Looking at the long-term picture, XENE's historical earnings data spans multiple years. The company achieved its highest annual net income of $13M in fiscal 2014.
Xenon Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), ACAD ($376M net income, 36.5% margin), PTCT (-$187M net income, 39.4% margin), XENE has comparable earnings metrics. Compare XENE vs PRAX →
XENE Earnings vs Peers
Earnings metrics vs comparable public companies
XENE Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$346M | -47.6% | -$373M | $-4.36 | -4612.1% | -4974.3% |
| 2024 | -$234M | -28.5% | -$279M | $-3.01 | - | - |
| 2023 | -$182M | -45.5% | -$214M | $-2.73 | - | - |
| 2022 | -$125M | -58.9% | -$129M | $-2.06 | -1328.9% | -1368.9% |
| 2021 | -$79M | -173.5% | -$79M | $-1.77 | -427.8% | -428.4% |
| 2020 | -$29M | +30.7% | -$31M | $-0.83 | -89.7% | -97.3% |
| 2019 | -$42M | -20.6% | -$43M | $-1.54 | -609.1% | -627.0% |
| 2018 | -$34M | -12.4% | -$38M | $-1.78 | - | - |
| 2017 | -$31M | -33.5% | -$33M | $-1.71 | -9872.7% | -10474.3% |
| 2016 | -$23M | -46.0% | -$25M | $-1.48 | -1275.5% | -1376.4% |
See XENE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XENE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XENE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXENE — Frequently Asked Questions
Quick answers to the most common questions about buying XENE stock.
Is XENE growing earnings?
XENE EPS fell to $-4.39, with earnings declining -44.9%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-383M.
What are XENE's profit margins?
Xenon Pharmaceuticals Inc. net margin is -4612.1%, with operating margin at -4974.3%. Below-average margins reflect competitive or cost pressures.
How consistent are XENE's earnings?
XENE earnings data spans 2012-2025. The declining earnings trend is -44.9% YoY. Historical data enables comparison across business cycles.